Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ablynx Says No Partner Required To Get Rare Disease Drug To Market

This article was originally published in Scrip

Executive Summary

Ablynx says it plans to retain 100% ownership of its thrombotic thrombocytopenic purpura (TTP) therapy, caplacizumab, rather than seek commercialization deals in Europe and the US following Phase III studies.

You may also be interested in...



In Vivo's Top M&A Of 2019: Cast Your Vote!

It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

In Vivo's Top Alliance Of 2019: Cast Your Vote!

It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

In Vivo's Top Financing Of 2019: Cast Your Vote!

It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029608

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel